Trevi Therapeutics (TRVI)

Trade TRVI now with
9/19/2022 7:32:47 AM Trevi Reports Positive Data From Phase 2 Trial Of Haduvio In Treatment Of Chronic Cough In Idiopathic Pulmonary Fibrosis
6/29/2022 7:36:16 AM Trevi Reports Positive Results From Ph2b/3 PRISM Trial Of Haduvio In Treatment Of Prurigo Nodularis
3/15/2022 7:36:49 AM Trevi Therapeutics Says Concludes Enrollment For Phase 2 CANAL Trial In IPF Chronic Cough
2/1/2022 7:40:13 AM Trevi Completes Enrollment For Phase 2b/3 PRISM Study In Chronic Pruritus In PN
1/5/2022 7:11:57 AM Trevi Expects To End Enrollment In Phase 2b/3 PRISM Trial For Pruritus Associated With PN By January 31, 2022
2/1/2021 7:37:09 AM Trevi Therapeutics Names William Forbes Chief Development Officer